Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 Accessibility StatementSkip Navigation 78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 Diabetes SAN DIEGO, March 26, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the completion of patient enrollment in its Phase 3 ...

The anti-obesity drug market is getting crowded. Many healthcare companies are working on their own GLP-1 drugs in an effort to take market share, which could amount to billions of dollars in revenue. The race is one for companies to get to the market as quickly as possible with an approved treatment. One stock that is in the thick of things right now is Viking Therapeutics (NASDAQ: VKTX). Although it doesn't have an approved drug just yet, it's moving in the right direction. And if it's successful, its sh ...

Viking Therapeutics ( VKTX ) has already completed enrollment of its VANQUISH-1 study of VK2735 in obesity, and its VANQUISH-2 study in type 2 diabetes/obesity is set to complete enrollment this quarter. Those studies will take 78 weeksScientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice.Analyst’s Disclosure: I ...

Every now and then, two investments land in front of you that look nothing alike but pose the same underlying questions: How much uncertainty are you willing to tolerate, and in what form? In that vein, Bitcoin (CRYPTO: BTC) and Viking Therapeutics (NASDAQ: VKTX) sit at opposite ends of the asset spectrum, with one being a cryptocurrency, and the other a pre-revenue biotech with some valuable intellectual property that's chasing a seat at the anti-obesity drug table. Both are genuinely compelling, but both ...

Core Insights - The article discusses the importance of staying updated on stocks in the biotech, pharma, and healthcare sectors, highlighting the trends and catalysts that influence market valuations [1] Group 1: Company Updates - Viking Therapeutics, Inc. (VKTX) was last updated in October, covering its Q3 earnings and business developments, with a consistent Buy rating issued for the sixth consecutive time [1] Group 2: Analyst Background - The analyst, Edmund Ingham, has over 5 years of experience in biotech consulting and has produced detailed reports on more than 1,000 companies, leading the investing group Haggerston BioHealth [1] Group 3: Investment Group Features - Haggerston BioHealth provides insights for both novice and experienced biotech investors, including catalysts to monitor, buy and sell ratings, product sales forecasts for major pharmaceutical companies, and comprehensive financial analyses [1]

Core Viewpoint - The weight loss drug market is emerging as a significant growth opportunity in the pharmaceutical industry, comparable to the technology sector, with Eli Lilly and Viking Therapeutics as key players [1][2]. Eli Lilly - Eli Lilly leads the weight loss drug market with a 60% share, driven by its products Mounjaro and Zepbound, which have shown triple-digit revenue growth [5][13]. - The company entered the GLP-1 drug market after Novo Nordisk and has focused on increasing manufacturing capacity to meet demand [4][5]. - Lilly's oral weight loss drug is currently under regulatory review, potentially expanding its market presence [6]. Viking Therapeutics - Viking Therapeutics is advancing its candidate VK2735 into phase 3 trials, with promising results suggesting it could compete effectively with Lilly and Novo's offerings [8][9]. - The company has another candidate targeting amylin and calcitonin receptors, which are important for metabolism [10]. - Demand for weight loss drugs is high, providing Viking with an opportunity to capture market share if its trials are successful [10]. Investment Considerations - Both Eli Lilly and Viking Therapeutics are viewed as strong investment opportunities in the weight loss drug market, with Lilly currently generating significant revenue and Viking showing potential for future growth [13][15]. - Lilly's stock has seen a decline of about 8% this year, trading at 28 times forward earnings estimates, while Viking's stock has increased by approximately 2% this year [13][14]. - The upcoming regulatory decision on Lilly's oral weight loss drug could serve as a catalyst for its stock price [15].

On February 17, 2026, ACT Capital Management disclosed a new position in Viking Therapeutics (NASDAQ:VKTX), acquiring 206,100 shares worth $7.25 million. What happened According to an SEC filing dated February 17, 2026, ACT Capital Management established a new position in Viking Therapeutics (NASDAQ:VKTX), adding 206,100 shares. The position’s value at quarter-end stood at $7.25 million. What else to know This is a new position, representing 5.86% of the fund’s reportable assets under management as of ...

Core Insights - Viking Therapeutics is a biotech company focused on innovative treatments for metabolic and endocrine disorders, particularly advancing its VK2735 program, a dual GLP-1/GIP agonist for obesity and diabetes [1] Stock Performance - Jefferies reiterated a "Buy" rating for VKTX on March 12, 2026, with the stock priced at $35.49, following a 16.5% rise in February after the release of the fourth-quarter earnings [2] - The current stock price of VKTX is $35.36, reflecting a decrease of approximately 1.13%, with a market capitalization of around $4.09 billion [4] - Over the past year, VKTX has fluctuated between a high of $43.15 and a low of $18.92, indicating significant volatility in its stock performance [4] Drug Development Focus - The VK2735 program, especially its oral formulation, is a key focus for investors, despite previous market disappointments with top-line results [3] - Viking Therapeutics is conducting two Phase 3 trials for the subcutaneous formulation of VK2735, with a maintenance study planned for 2026 to assess the tolerability of the oral formulation [3]

Company Overview - Shares in Viking Therapeutics (NASDAQ: VKTX) rose by 16.5% in February, contributing to a recovery in 2026, with the stock currently down by a low single-digit percentage this year [1] - The increase followed the company's fourth-quarter earnings release and corporate update [1] Pipeline Developments - The primary focus for Viking Therapeutics is its VK2735 development program, a dual GLP-1/GIP agonist aimed at treating obesity and diabetes, currently in trials for both subcutaneous and oral forms [2] - The oral formulation of VK2735 has generated significant excitement due to its advantages, such as avoiding injections and ease of storage [5] Clinical Trial Insights - The Phase 2 VENTURE trial for oral VK2735 showed a mean weight loss of up to 12.2% after 13 weeks, but faced criticism due to a 20% discontinuation rate from adverse events [5] - Adverse events primarily included gastrointestinal issues like nausea, vomiting, and diarrhea, raising concerns about the safety and tolerability of the oral formulation [5] - The placebo group had a 13% discontinuation rate due to adverse events, indicating challenging characteristics within the overall cohort [6] Future Studies - The company has initiated a maintenance and transition study where participants will start with subcutaneous VK2735 and then transition to a maintenance dosage in either subcutaneous or oral form [7] - This study is fully enrolled, with results expected to be announced in the third quarter of 2026 [7]

Group 1 - Viking Therapeutics (VKTX) stock received an upgrade in its Relative Strength (RS) Rating from 61 to 72, indicating a positive trend but still below the preferred benchmark of 80 or higher [1] - The stock has reclaimed its 50-day moving average in the last three trading days, suggesting potential for further recovery [1] - The company reported 0% growth in earnings per share (EPS) and sales in the last quarter, indicating stagnation in financial performance [1] Group 2 - Viking Therapeutics ranks No. 312 among its peers in the Medical-Biomed/Biotech industry group, highlighting its relative position within the sector [1] - Other highly rated stocks in the same industry include Kiniksa Pharmaceuticals (KNSA), Aurinia Pharmaceuticals (AUPH), and Amicus Therapeutics (FOLD) [1]